KETAMINA NO MANEJO FARMACOLÓGICO AGUDO DA IDEAÇÃO SUICIDA
DOI:
https://doi.org/10.29237/2358-9868.2019v7i1.p131-141Palavras-chave:
Suicídio, Ideação Suicida, KetaminaResumo
Objetivo: A ideação suicida é a emergência psiquiátrica mais frequentemente encontrada no contexto emergencial. Entretanto, devido à complexa interação entre seus fatores de risco, desconforto do paciente em abordar a temática, individualidade clínica dos episódios e déficit de intervenções farmacológicas eficazes, são escassos os protocolos que forneçam algoritmos para o manejo da entidade. Apesar de recentemente ter sido demonstrada a eficácia do uso de Ketamina no manejo da depressão, pouco se sabe sobre sua eficácia no manejo da ideação suicida. Nesta revisão foram avaliados ensaios clínicos que versam sobre o uso da ketamina no tratamento agudo da ideação suicida associada ou não a transtornos depressivos, de forma a determinar se o uso do fármaco é seguro e eficaz no manejo dessa emergência psiquiátrica. Fontes de dados: Foram realizadas buscas nas bases de dados PubMed, SciELO, Web of Science, Bireme e Scopus com os termos MeSH “Ketamine” e “Suicide ideation”. Síntese dos dados: Após a seleção, sem limites temporais, de ensaios clínicos randomizados e exclusão das duplicatas, foram incluídos 10 estudos nesta revisão. Conclusões: Os trabalhos demonstraram que a Ketamina é um fármaco de ação rápida e possivelmente sustentada na ideação suicida, bem como de efeitos adversos leves e auto-limitados. Entretanto, tais resultados devem ser reproduzidos em um maior número de pacientes, principalmente no que diz respeito ao uso de doses de manutenção.
Referências
2. Center for Disease Control and Prevention. Ten Leading Causes of Death by Age Group, United States - 2014. National Vital Statistics, National Center for Health Statistics. 2016. p. 1–1.
3. Wen B, Lampe JN, Roberts AG, Atkins WM, Rodrigues AD, Nelson SD. Cross-National Prevalence and Risk Factors for Suicidal Ideation, Plans, and Attempts. Br J Psychiatry. 2008;454(192):98–108.
4. Nock MK, Hwang I, Sampson N, Kessler RC, Angermeyer M, Beautrais A, et al. Cross-national analysis of the associations among mental disorders and suicidal behavior: Findings from the WHO World Mental Health Surveys. PLoS Med. 2009;6(8).
5. Reinstatler L, Youssef NA. Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs R D. 2015;15(1):37–43.
6. Bentley SM, Pagalilauan GL, Simpson SA. Major Depression. Med Clin North Am. 2014;98(5):981–1005.
7. Association AP. Diagnostic and Statistical Manual of Mental disorders - DSM-5. American P. Washington: Artmed; 2013.
8. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. Vol. 8, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. 2007. 67-104 p.
9. Pu J, Zhou X, Liu L, Zhang Y, Yang L, Yuan S, et al. Efficacy and acceptability of interpersonal psychotherapy for depression in adolescents: A meta-analysis of randomized controlled trials. Psychiatry Res. Elsevier Ireland Ltd; 2017;253:226–32.
10. Wheat S, Dschida D, Talen MR. Psychiatric Emergencies. Prim Care - Clin Off Pract. 2016;43(2):341–54.
11. LLC THA. Micromedex® Healthcare Series. Thomson Healthcare. 2017.
12. Al Jurdi RK, Swann A, Mathew SJ. Psychopharmacological Agents and Suicide Risk Reduction: Ketamine and Other Approaches. Curr Psychiatry Rep. 2015;17(10).
13. Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M, et al. Ketamine administration in depressive disorders: A systematic review and meta-analysis. Psychopharmacology (Berl). 2014;231(18):3663–76.
14. Murrough JW, Soleimani L, DeWilde KE, Collins K a, Lapidus K a, Iacoviello BM, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med. 2015;ePub(ePub):ePub-ePub.
15. Kashani P, Yousefian S, Amini A, Heidari K, Younesian S, Hatamabadi HR. The Effect of Intravenous Ketamine in Suicidal Ideation of Emergency Department Patients. Emerg (Tehran, Iran). 2014;2(1):36–9.
16. Diazgranados, Nancy; ibrahim, Lobna; Brutsche, Nancy; Ameli, Rezvan; Henter, Ioline; Luckenbaurgh, David; Machado-Vieira, Rodrigo; Zarate C. Rapid resolution of suicidal ideation after a single infusion of an NMDA antagonist in patients with treatment-resistent major depressive disorder. J Clin Psychiatry. 2010;71(12):1605–11.
17. Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biol Psychiatry. Elsevier Inc.; 2012;71(11):939–46.
18. Hu YD, Xiang YT, Fang JX, Zu S, Sha S, Shi H, et al. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study. Psychol Med. 2015;46:1–13.
19. Voort JL, Morgan RJ, Kung S, Rasmussen KG, Rico J, Palmer BA, et al. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. Elsevier; 2016;206:300–4.
20. Burger J, Capobianco M, Lovern R, Boche B, Ross E, Darracq MA, et al. A Double-Blinded, Randomized, Placebo-Controlled Sub-Dissociative Dose Ketamine Pilot Study in the Treatment of Acute Depression and Suicidality in a Military Emergency Department Setting. Mil Med. 2016;181(10):1195–9.
21. Larkin GL, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14(8):1127–31.
22. Price RB, Iosifescu D V, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ, et al. Effects of Ketamine on Explicit and Implicit Suicidal Cognition: a Randomized Controlled Trial in Treatment-Resistant Depression. Depress Anxiety. 2014;31(4):335–43.
23. Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, et al. Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety. J Psychiatr Res. 2014;58:161–6.
